Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study

View Full Paper
Ask AI
Bookmark
Share

Authors

CHCraig C. HofmeisterBBB. BurtonLBLawrence Boise

Discussion

Loading...

Member takes

Overview

Randomized Phase II trial compared outcomes of daratumumab and ixazomib vs bortezomib in multiple myeloma, revealing improved results with DId regimen.

Key Points

  • To evaluate the safety and efficacy of daratumumab-based induction therapies in newly diagnosed multiple myeloma.
  • Conducted a randomized Phase II study with two arms: DId and DVd.
  • Enrolled 52 subjects at Winship Cancer Institute from July 2019 to May 2022.
  • Analyzed primary endpoint of very good partial response rate post-induction cycle.
  • Arm B (DVd) achieved a higher ≥ VGPR rate than Arm A (DId): 56.5% vs 28%.
  • Overall response rate favored Arm B: 95.7% vs 76%.
  • 40-month progression free survival was 90% in Arm B compared to 67% in Arm A.

Cite This Study

Hofmeister et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d15dhttps://doi.org/10.1182/blood-2025-5843
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of daratumumab plus carfilzomib-based induction/consolidation/maintenance therapy with autologous stem cell transplantation in transplant-eligible ultra high-risk newly diagnosed multiple myeloma: Preliminary results2025
  2. 2Isatuximab (Isa) plus lenalidomide (R), Bortezomib (V), and dexamethasone (d) (Isa-RVd) as induction therapy in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Primary analysis of parallel phase 2 studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI)2025
  3. 3Role of Daratumumab, Lenalidomide, and Dexamethasone in Transplantation-Eligible Patients with Multiple Myeloma After the Failure of Bortezomib-Based Induction Therapy2025
  4. 4Role of bortezomib maintenance therapy in the anti-CD38 antibody era: Interim analysis results of a randomized Phase III study for transplant-ineligible newly diagnosed multiple myeloma (JCOG1911/B-DASH Study)2025 · 1 citations
  5. 5Real-world stratified treatment strategies in transplant-eligible newly diagnosed multiple myeloma: A multicohort study2025